Publications by authors named "George Demos"

Claim this Profile
C
Clinical outcomes and treatment patterns of older adults with dementia-related psychosis by dementia type in the United States.
Joan Forns, Heather E Danysh, Lisa J McQuay, Mary Ellen Turner, Colleen Dempsey, George Demos

BMC Geriatr· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis.
Ismaeel Yunusa, Nazia Rashid, George N Demos, Bhargavi S Mahadik, Victor C Abler

Adv Ther· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Falls and Fractures in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study.
J Bradley Layton, Joan Forns, Mary Ellen Turner, Colleen Dempsey, Jennifer L Bartsch, George Demos

Drugs Real World Outcomes· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased risk of falls and fractures in patients with psychosis and Parkinson disease.
Joan Forns, J Bradley Layton, Jennifer Bartsch, Mary Ellen Turner, Colleen Dempsey, George Demos

PLoS One· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis.
Clive G Ballard, David L Kreitzman, Stuart Isaacson, I-Yuan Liu, James C Norton, George Demos

Parkinsonism Relat Disord· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pimavanserin for the treatment of Parkinson's disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Leslie Citrome, James C Norton, Kathy Chi-Burris, George Demos

CNS Spectr· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
Clive Ballard, Carol Banister, Zunera Khan, Jeffrey Cummings, George Demos

Lancet Neurol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bimatoprost 0.03% for the Treatment of Eyelash Hypotrichosis: A Pooled Safety Analysis of Six Randomized, Double-masked Clinical Trials.
David Wirta, David M Pariser, Steven G Yoelin, Seiji Arase, Amy McMichael, George Demos

J Clin Aesthet Dermatol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications.
Markus Naumann, Alastair Carruthers, Jean Carruthers, Sheena K Aurora, Ross Zafonte, George Demos

Mov Disord· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants.
Mitchell F Brin, Terry I Boodhoo, Janice M Pogoda, Lynn M James, George Demos

J Am Acad Dermatol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis